uniQure N.V. (NASDAQ:QURE – Free Report) – Research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of uniQure in a report released on Thursday, September 25th. In the last ninety days, insiders have sold 244,316 shares of company stock valued at $10,328,181. Mraz Amerine & Associates Inc. acquired a new position in shares of uniQure in the 1st quarter valued at about $106,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of uniQure in the 1st quarter valued at about $152,000. uniQure Company Profile(Get Free Report)uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases.